Analytical Data
-
Gene name
isaA
- Application
-
Alternative Names
Immunodominant staphylococcal antigen A
-
Species
Staphylococcus aureus
-
Source
E. coli
-
Tag
N- His & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P60157
-
Expression Region
30-233aa
-
Molecular Weight
28.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IsaA is a protein associated with the pathogenicity of various infectious agents, particularly in the context of bacterial infections. It plays a crucial role in the host-pathogen interaction, influencing the virulence and immune evasion strategies of bacteria. Research into IsaA recombinant protein has gained momentum due to its potential as a novel target for vaccine development and therapeutic interventions. The understanding of its structure and function is vital as it may facilitate the design of effective immunogenic constructs that can stimulate a robust immune response. Furthermore, studies have demonstrated that IsaA is involved in the regulation of key biological processes within the pathogen, making it a promising candidate for further exploration. By investigating the genetic and biochemical properties of IsaA, researchers aim to gain insights into the molecular mechanisms governing bacterial virulence and host responses, ultimately paving the way for innovative treatment strategies. The generation of recombinant IsaA protein allows for detailed studies on its immunological properties, offering evidence for its potential role as a vaccine candidate to prevent infections caused by IsaA-expressing pathogens. The ongoing research highlights the need for comprehensive studies to fully elucidate the implications of IsaA in microbial pathogenesis and its prospects in clinical applications, thereby establishing a foundation for future advancements in targeted therapies and vaccine development.
